Results 251 to 260 of about 214,611 (264)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis

Cancers, 2021
Martine Piccart, Evandro de Azambuja, Danai Fimereli   +2 more
exaly  

Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations

Cancer Cell, 2018
Natalia Jura, Marco Mravic, Kumar Prabhash   +2 more
exaly  

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort

Annals of Oncology, 2016
Julien Mazieres, Federico Cappuzzo, Thomas Filleron   +2 more
exaly  

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Annals of Oncology, 2015
Giuseppe Giaccone, D R Camidge, B T Li
exaly  

Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients

Annals of Oncology, 2013
Federico Piacentini, P F Conte, C Omarini   +2 more
exaly  

Inhibition of HER2-Positive Breast Cancer Growth by Blocking the HER2 Signaling Pathway with HER2-Glycan-Imprinted Nanoparticles

Angewandte Chemie - International Edition, 2019
Zhen Liu, Rongrong Xing
exaly  

Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

Annals of Oncology, 2016
Federico Piacentini, Pierfranco Conte, Enrico Tagliafico   +2 more
exaly  

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab†

Annals of Oncology, 2016
Emilio Bria, V Guarneri, C Schem
exaly  

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

Annals of Oncology, 2010
Hideaki Shimada, Mukohara Toru
exaly  

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.

Ca-A Cancer Journal for Clinicians
Carlos Barcenas, Suzanne A W Fuqua, Senthil Damodaran   +2 more
exaly